Fixed drug eruption: The dark side of activation of intraepidermal CD8+T cells uniquely specialized to mediate protective immunity

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 106-121

  Shiohara, Tetsuo ^a   Mizukawa, Yoshiko ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; CODEINE; GAMMA INTERFERON; IBUPROFEN; MEFENAMIC ACID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYPHENBUTAZONE; PHENOLPHTHALEIN; PSEUDOEPHEDRINE; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULITIS; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; ERYTHEMA MULTIFORME; FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; IMMUNITY; LICHEN PLANUS; NONHUMAN; PARAPSORIASIS; PARONYCHIA; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS;

ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EPIDERMIS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; VIRUS DISEASES;

EID: 84926093213     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335623     Document Type: Article

References (61)

1. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 2001;45:712-717.
2. Shiohara T: Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009;9:316-321.
3. Savin JA: Current causes of fixed drug eruption in the UK. Br J Dermatol 2001;145:667-670.
4. Shiohara T, Moriya N: Epidermal T cells: their functional role and disease relevance for dermatologists. J Invest Dermatol 1997;109:271-275.
5. Mizukawa Y, Yamazaki Y, Terraki Y, Hayakawa J, Hayakawa K, Nuriya H, Kohara M, Shiohara T: Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002;161: 1337-1347.
6. Shiohara T, Mizukawa Y, Teraki Y: Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002;2: 317-323.
7. Shiohara T, Mizukawa Y: Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007;17:201-208.
8. Mizukawa Y, Shiohara T: Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Clin Exp Dermatol 2010; 35:493-497.
9. Ruocco V, Ruocco E, Ghersetich I, Bianchi B, Lotti T: Isotopic response after herpesvirus infection: an update. J Am Acad Dermatol 2002;46:90-94.
10. Shiohara T, Mizukawa Y: Recall phenomenon: some skin-resident cells remember previous insults. Dermatol 2003;207:127-129.
11. Korkij W, Soltani K: Fixed drug eruption. Arch Dermatol 1984;120:520-524.
12. Mizukawa Y, Shiohara T: Trauma-localized fixed drug eruption: involvement of burn scars, insect bites and venipuncture sites. Dermatology 2002;205: 159-161.
13. Mizukawa Y, Yamazaki Y, Shiohara T: In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol 2008;158:1230-1238.
14. Shelley WB, Shelley ED: Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J Am Acad Dermatol 1987;17:403-407.
15. Shiohara T, Mizukawa Y: Fixed drug eruption: easily overlooked but needing new respect. Dermatology 2002;51:469-472.
16. Gruber F, Stasic A, Lenkovic M, Brajac I: Postcoital fixed drug eruption in a man sensitive to trimethoprim-sulphamethoxazole. Clin Exp Dermatol 1997;22:144-145.
17. Guin JD, Haynie LS, Jackson D, Baker GF: Wandering fixed drug eruption: a mucocutaneous reaction to acetaminophen. J Am Acad Dermatol 1987;17: 399-402.
18. Shiohara T, Kokaji T: Polysensitivity in fixed drug eruption. J Am Acad Dermatol 1997;37:1017-1018.
19. Verbov J: Fixed drug eruption due to a drug combination but not to its constituents. Dermatologica 1985;171:60-61.
20. Keiso JM: Fixed food eruption. J Am Acad Dermatol 1996;35:638-639.
21. Yanguas I, Oleaga JM, González-Güemes M, Goday JJ, Soloeta R: Fixed food eruption caused by lentils. J Am Acad Dermatol 1998;38:640-641.
22. Volz T, Berner D, Weigert C, Röcken M, Biedermann T: Fixed food eruption caused by asparagus. J Allergy Clin Immunol 2005;116:1390-1392.
23. Pellicano R, Camassa F, Lomuto M: Localized dermographism at the site of a fixed drug eruption. Br J Dermatol 1995;132:156-158.
24. Del Rio E, Guimaraens D, Aguilar A, Conde-Salazar L, Sánchez Yus E: Fixed exanthema induced by ultraviolet radiation. Dermatology 1996;193:54-55.
25. Kelso JM, Keating RM: Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol 1996;97:1171-1172.
26. Desmeules H: Nonpigmenting fixed drug eruption after anesthesia. Anesth Analg 1990;70:216-217.
27. Sigal-Nahum M, Konqui A, Gaulier A, Sigal S: Linear fixed drug eruption. Br J Dermatol 1988;118: 849-851.
28. Senturk N, Yanik F, Yildiz L, Aydin F, Canturk T, Turanli AY: Topotecan-induced celluitis-like fixed drug eruption. J Eur Acad Dermatol Venereol 2002; 16:414-416.
29. Baran R, Perrin C: Fixed-drug eruption presenting as an acute paronychia. Br J Dermatol 1991;125: 592-595.
30. Flax SH, Uhle P: Photo recall-like phenomenon following the use of cefazolin and gentamicin sulfate. Cutis 1990;46:59-61.
31. Goldfeder KL, Levin JM, Katz KA, Clarke LE, Loren AW, James WD: Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy. J Am Acad Dermatol 2007;56:494-499.
32. Guin JD, Baker GF: Chronic fixed drug eruption caused by acetaminophen. Cutis 1988;4:106-108.
33. Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R: Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991;24:216-220.
34. Shiohara T, Mizukawa Y: The immunological basis of lichenoid tissue reaction. Autoimmune Rev 2005; 4:236-241.
35. Agnew KI, Liver GF: Neutrophilic fixed drug eruption. Australas J Dermatol 2001;42:200-202.
36. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321-328.
37. Pichler WJ, Tilch J: The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809-820.
38. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T: Defective regulatory T cells in patients with severe drug eruption: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009;182: 8071-8079.
39. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R: Protection of the intestinal mucosa by intraepithelial γδ T cells. Proc Natl Acad Sci USA 2002;99: 14338-14343.
40. Shiohara T, Mizulawa Y, Teraki Y, Fukuda T: Gamma-delta T cells with emphasis on their functional role in the epidermis. Chem Immunol 2001; 79:66-86.
41. Komatsu T, Moriya N, Shiohara T: T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR Vα-Vβ genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Immunol 1996;104:343-350.
42. Shiohara T, Mizukawa Y, Teraki Y: Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002;2: 317-323.
43. Havran WL, Chien YH, Allison JP: Recognition of self antigens by skin-derived T cells with invariant γδ antigen receptors. Science 1991;252:1430-1432.
44. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC: Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-609.
45. Shiohara T, Moriya N, Hayakawa J, Itohara S, Ishikawa H: Resistance to cutaneous graft-vs.-host disease is not induced in T cell receptor δ genemutant mice. J Exp Med 1996;183:1483-1489.
46. Sharp LL, Jameson JM, Cauvi G, Havran WL: Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. Nat Immunol 2005;6:73-79.
47. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
48. Masopust D, Vezys V, Marzo AL, Lefrançois L: Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-2417.
49. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
50. Ely KH, Roberts AD, Woodland DL: Cutting edge: effector memory CD8+ T cells in the lung airways retain the potential to mediate recall responses. J Immunol 2003;171:3338-3342.
51. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR: Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009;10:524-530.
52. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L: Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603.
53. van Panhuys N, Perret R, Prout M, Ronchese F, Le Gros G: Effector lymphoid tissue and its crucial role in protective immunity. Trends Immunol 2005;26: 242-247.
54. Shiohara T, Mizukawa Y, Takahashi R, Kano Y: Pathomechanisms of lichen planus. Autoimmunity elicited by cross-reactive T cells; in Nickoloff BJ, Nesle FO (eds): Dermatologica Immunity. Curr Dir Autoimmun. Basel, Karger, 2008, pp 206-226.
55. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW 4th: Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007;447:326-329.
56. Hansen SG,Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15:293-299.
57. Burrows SR, Khanna R, Burrows JM, Moss DJ: An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994;179: 1155-1161.
58. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP: T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 1995;182:1703-1715.
59. Burrows SR, Silins SL, Khanna R, Burrows JM, Rischmueller M, McCluskey J, Moss DJ: Crossreactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 1997;27: 1726-1736.
60. Archbold JK, Macdonald WA, Gras S, Ely LK, Miles JJ, Bell MJ, Brennan RM, Beddoe T, Wilce MC, Clements CS, Purcell AW, McCluskey J, Burrows SR, Rossjohn J: Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J Exp Med 2009;206:209-219.
61. Archbold JK, Ely LK, Kjer-Nielsen L, Burrows SR, Rossjohn J, McCluskey J, Macdonald WA: T cell allorecognition and MHC restriction -a case of Jekyll and Hyde? Mol Immunol 2008;45:583-598.